LISNOPRIL/HCTZ (TYPE P) TABLET

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

LISINOPRIL (LISINOPRIL DIHYDRATE); HYDROCHLOROTHIAZIDE

Tersedia dari:

SANIS HEALTH INC

Kode ATC:

C09BA03

INN (Nama Internasional):

LISINOPRIL AND DIURETICS

Dosis:

20MG; 12.5MG

Bentuk farmasi:

TABLET

Komposisi:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG; HYDROCHLOROTHIAZIDE 12.5MG

Rute administrasi :

ORAL

Unit dalam paket:

30/100

Jenis Resep:

Prescription

Area terapi:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Ringkasan produk:

Active ingredient group (AIG) number: 0222417001; AHFS:

Status otorisasi:

CANCELLED PRE MARKET

Tanggal Otorisasi:

2018-07-16

Karakteristik produk

PRODUCT MONOGRAPH
Pr
LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin Converting Enzyme Inhibitor/Diuretic
Sanis Health Inc.
333 Champlain Street, Suite 102
Dieppe, New Brunswick
Canada, E1A 1P2
Submission Control No: 144791
Date of Preparation:
February 8, 2011
Page 2
PRODUCT MONOGRAPH
Pr
LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin-Converting Enzyme Inhibitor/Diuretic
ACTION AND CLINICAL PHARMACOLOGY
LISINOPRIL/HCTZ (TYPE P) (lisinopril and hydrochlorothiazide tablets)
combines the action
of an angiotensin-converting enzyme (ACE) inhibitor, lisinopril, and a
diuretic,
hydrochlorothiazide.
LISINOPRIL
Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum potassium. In patients
treated with lisinopril plus a
thiazide diuretic, there was essentially no change in serum potassium
(see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
Page 3
PHARMACODYNAMICS
LISINOPRIL
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of lisinopril has not
been associated with a ra